Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition space

The company, a joint venture between Dr Reddys Laboratories and Nestle India Ltd, said Celevida GLP is a specialised scientifically designed product to support optimum nutrition intake and muscle mass maintenance for sustaining metabolic and functional health for people undergoing GLP-1GIP therapy for management of type 2 diabetes and obesity in India.

Dr Reddy's and Nestle Health Science Ltd on Thursday announced strengthening of presence in diabetes and obesity nutrition space with the launch of 'Celevida GLP+'. The company, a joint venture between Dr Reddy's Laboratories and Nestle India Ltd, said Celevida GLP+ is a specialised scientifically designed product to support optimum nutrition intake and muscle mass maintenance for sustaining metabolic and functional health for people undergoing ''GLP-1/GIP therapy'' for management of type 2 diabetes and obesity in India. ''GLP-1 therapies represent a significant advancement in diabetes and obesity management. However, a clear unmet need remains in supporting patients beyond pharmacological treatment, particularly in addressing nutrition gaps and preserving muscle health during therapy,'' Dr Reddy's Laboratories CEO, Global Generics and Dr Reddy's and Nestle Health Science Ltd Director, MV Ramana said. As patients experience changes in body composition, ensuring adequate nutrient intake and maintaining lean body mass become critical to sustaining long-term outcomes, he added. ''With Celevida GLP+, we aim to address this gap through a targeted, science-backed nutritional solution that complements pharmacological therapies and supports better overall patient outcomes in their everyday journey,'' Ramana said.